ALL-410 In-depth Responder Analysis of PhALLCON, a Phase 3 Trial of Ponatinib Versus Imatinib in Newly Diagnosed Ph+ ALL
Year: 2024
Type: conference-abstract
Authors: Elias Jabbour, Hagop Kantarjian, Ibrahim Aldoss, Pau Montesinos, Jessica T. Leonard, David Gomez-Almaguer, Maria R. Baer, Carlo Gambacorti-Passerini, James McCloskey, Yosuke Minami, Cristina Papayannidis, Philippe Rousselot, Pankit Vachhani, Eunice S. Wang, Lin Yang, Meliessa Hennessy, Alexander Vorog, Niti Patel, Jose-Maria Ribera-Santasusana
Institutions: The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, Hospital Universitari i Politècnic La Fe, Oregon Health & Science University, Universidad Autónoma de Nuevo León, Hospital Universitario Dr José Eleuterio Gonzalez, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Milano-Bicocca, Hackensack University Medical Center, National Cancer Center Hospital East, Istituto di Ematologia di Bologna, Centre Hospitalier de Versailles, University of Alabama at Birmingham, Roswell Park Comprehensive Cancer Center, Josep Carreras Leukaemia Research Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4401876090